A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · cited 3×
“…JAK 2 V617F mutation, haemoglobin concentration and/or Hct are currently used as a surrogate for RCM to distinguish between PV and essential thrombo-cythaemia (ET) (Arber et al , 2016), but Hct has the better accuracy in predicting RCM (Alvarez-Larr (cid:1) an et al , 2012; Ancochea et al , 2014).”
BackgroundMethodAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 2×
“However, the JAK 2 V617F mutation has been identified in normal individuals, often at a low allele burden, with a frequency that increases with age (Gen-ovese et al , 2014; Jaiswal et al , 2014).”
BackgroundClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276 · cited 2×
“…patients with exon 12 mutated-PV tend to be younger, with higher haemoglobin concentrations, lower white blood cell (WBC) and platelet counts, and an isolated increase in erythropoiesis without granulocytic or megakaryocytic morphological abnormalities (Scott et al , 2007; Passamonti et al , 2011).”
BackgroundSelf-citationEfficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891 · cited 2×
“Following this, a phase III trial RESPONSE evaluated the efficacy and safety of ruxolitinib in a specific subgroup of PV patients who were both refractory to, or intolerant of, HC and who required ongoing phlebotomy and had splenomegaly (Vannucchi, 2015).”
MethodSelf-citationCardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846 · cited 5×
“This target has now been validated in a randomised clinical trial by the Cytoreductive Therapy in PV (CYTO-PV) investigators who assessed the impact of stringent Hct reduction to 0 (cid:1) 45 compared with a more liberal target range of 0 (cid:1) 45 – 0 (cid:1) 50 (Marchioli et al , 2013).”
BackgroundMethodInfluentialHydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843 · cited 1×
“The efficacy of HC in controlling blood counts and preventing thrombosis has been extrapolated from the evidence in ET (Cortelazzo et al , 1995) and HC has been used in the management of PV.”
MethodVascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G., & Barbui, T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.062 · Cited by 726 · cited 3×
“At diagnosis, in the largest prospective study to date, the European Collaboration on Low-Dose Aspirin in Poly-cythaemia Vera (ECLAP), age ≥ 65 years and a prior history of thrombosis were found to be the most important predictors of cardiovascular events (Marchioli et al , 2005).”
BackgroundTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700 · cited 9×
“A long-term assessment from the ECLAP study showed no increased MDS/AML in those treated with HC alone (Finazzi et al , 2005) and a retrospective analysis showed no association between HC or busulfan and AML (Tefferi et al , 2013).”
BackgroundMethodInfluentialDiagnosis and classification of the polycythemias.
Berlin, N. I. (1975) · PubMed · Cited by 541
Finazzi, G. (2005) · Blood · doi:10.1182/blood-2004-09-3426 · Cited by 431 · cited 4×
“At diagnosis, in the largest prospective study to date, the European Collaboration on Low-Dose Aspirin in Poly-cythaemia Vera (ECLAP), age ≥ 65 years and a prior history of thrombosis were found to be the most important predictors of cardiovascular events (Marchioli et al , 2005).”
BackgroundInfluentialQuintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G., Marchioli, R., & for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) (2007) · Blood · doi:10.1182/blood-2006-08-042515 · Cited by 416 · cited 3×
“A base-line WBC count of > 15 (cid:1) 0 9 10 9 /l is a significant predictor of thrombosis, particularly an increased risk of myocardial infarction (Landolfi et al , 2007); however, prognostic models including leucocytosis have not been prospectively validated.”
BackgroundVASCULAR OCCLUSIVE EPISODES AND VENOUS HÆMATOCRIT IN PRIMARY PROLIFERATIVE POLYCYTHÆMLX
Pearson, T. C., & Wetherley-Mein, G. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92098-6 · Cited by 381 · cited 1×
“The target for Hct control in PV was originally based on data from assessment of numbers of vascular events at different Hct levels and it was estimated that a target below 0 (cid:1) 45 should be maintained (Pearson & Wetherley-Mein, 1978).”
BackgroundPassamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.148 · Cited by 370 · cited 4×
“In contrast, one prospective study did not find such an association (Passamonti et al , 2010).”
BackgroundInfluentialProspective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V, Bogani, C., Ferrini, P. R., Rambaldi, A., Guerini, V, et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404854 · Cited by 368 · cited 1×
“…features at presentation, including higher haemoglobin levels, higher WBC counts, lower platelet counts, lower mean cell volume (MCV), lower serum ferritin and EPO, more splenomegaly and more pruritus (Dupont et al , 2007; Tefferi et al , 2007; Vannucchi et al , 2007; Passamonti et al , 2010).”
BackgroundGuidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis
McMullin, M. F., Bareford, D., Campbell, P., Green, A. R., Harrison, C., Hunt, B., Oscier, D., Polkey, M. I., Reilly, J. T., Rosenthal, E., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05535.x · Cited by 343 · cited 2×
“The previous guideline was published in 2005 (McMullin et al , 2005) with an amendment in 2007 (McMullin et al , 2007) to update the diagnostic criteria following the discovery of the JAK 2 mutation in patients with polycythaemia vera (PV).”
MethodSelf-citationPearson, T. C., Guthrie, D. L., Simpson, J., Chinn, S., Barosi, G., Ferrant, A., Lewis, S. M., & Najean, Y. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08411.x · Cited by 321 · cited 1×
“An RCM more than 25% above the mean predicted value is diagnostic of an absolute erythrocytosis (Pearson et al , 1995).”
BackgroundTargeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y., Pacilli, A., Hanson, C. A., Pancrazzi, A., Ketterling, R. P., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000216 · Cited by 311 · cited 1×
“Targeted gene sequencing is a rapidly advancing area; approximately 15% of PV patients have mutations of ≥ 1 of ASXL1 , SRSF2 and IDH2 and these patients have a reduced rate of overall survival in univariate analysis (Tefferi et al , 2016).”
BackgroundHigh molecular response rate of polycythemia vera patients treated with pegylated interferon -2a
Kiladjian, J., Cassinat, B., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Menot, M.-L., Massonnet, G., Dutel, J.-L., Ghomari, K., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009860 · Cited by 264 · cited 1×
“…of 70 – 95% as well as complete molecular remissions of 14 – 24%, with treatment discontinuation due to side-effects observed in only 8 – 10% of patients (Kiladjian et al , 2006) (Quint (cid:1) as-Cardama et al , 2009) Comparable results have been noted in single-centre studies (Cris (cid:4) a et…”
ResultPassamonti, F., Griesshammer, M., Palandri, F., Egyed, M., Benevolo, G., Devos, T., Callum, J., Vannucchi, A. M., Sivgin, S., Bensasson, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30558-7 · Cited by 260 · cited 1×
“Following RESPONSE, a second randomized open label phase 3b study (RESPONSE-2) was developed to determinate the efficacy of ruxolitinib versus BAT in a similar population of PV patients as RESPONSE but the patients were not required to have splenomegaly (Passamonti et al , 2017).”
MethodKiladjian, J.-J., Chevret, S., Dosquet, C., Chomienne, C., & Rain, J.-D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0792 · Cited by 255 · cited 1×
“…T. (2010) Pipobroman, a bromide derivative of piperazine similar to alkylating agents, has been compared to HC in randomised trials and shown to be effective but has continuing leukae-mogenic potential (Kiladjian et al , 2011) and therefore should only be used in those with limited life expectancy.”
BackgroundBjörkholm, M., Derolf, Å. R., Hultcrantz, M., Kristinsson, S. Y., Ekstrand, C., Goldin, L. R., Andreasson, B., Birgegård, G., Linder, O., Malm, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7542 · Cited by 245 · cited 1×
“Whilst the risk of AML/MDS was increased in patients exposed to high doses of 32 P and alkylators or 2 or more cytoreductive agents, this was not seen in those patients treated exclusively with HC (Bj € orkholm et al , 2011).”
BackgroundPassamonti, F., Elena, C., Schnittger, S., Skoda, R. C., Green, A. R., Girodon, F., Kiladjian, J.-J., McMullin, M. F., Ruggeri, M., Besses, C., et al. (2011) · Blood · doi:10.1182/blood-2010-11-316810 · Cited by 236 · cited 2×
“Although JAK2 exon12-mutated disease has a subtly different clinical phenotype to JAK2 V617F -driven PV (higher haemoglobin concentration, lower WBC count), there appears to be no difference in long-term prognosis (Passamonti et al , 2011).”
BackgroundSelf-citationAlvarez-Larrán, A., Pereira, A., Cervantes, F., Arellano-Rodrigo, E., Hernández-Boluda, J.-C., Ferrer-Marín, F., Angona, A., Gómez, M., Muiña, B., Guillén, H., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387787 · Cited by 234
Dupont, S., Massé, A., James, C., Teyssandier, I., Lécluse, Y., Larbret, F., Ugo, V., Saulnier, P., Koscielny, S., Le Couédic, J. P., et al. (2007) · Blood · doi:10.1182/blood-2006-10-054940 · Cited by 197 · cited 1×
“…features at presentation, including higher haemoglobin levels, higher WBC counts, lower platelet counts, lower mean cell volume (MCV), lower serum ferritin and EPO, more splenomegaly and more pruritus (Dupont et al , 2007; Tefferi et al , 2007; Vannucchi et al , 2007; Passamonti et al , 2010).”
BackgroundThe haematocrit and platelet target in polycythemia vera
Di Nisio, M., Barbui, T., Di Gennaro, L., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G., Marfisi, R., Porreca, E., Ruggeri, M., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06430.x · Cited by 183 · cited 1×
“A relationship between thrombocytosis (either at diagnosis or follow-up) and thrombotic risk has not been established in PV (Di Nisio et al , 2007), but extreme thrombocytosis ( ≥ 1500 9 10 9 /l) is associated with increased risk of bleeding due to acquired von Willebrand disease and should be…”
BackgroundVerstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P. J., Rumi, E., Gattoni, E., Pieri, L., Guglielmelli, P., Elena, C., et al. (2014) · Cancer · doi:10.1002/cncr.28441 · Cited by 179 · cited 1×
“(Verstovsek et al , 2014).”
McMullin, M. F., Mead, A. J., Ali, S., Cargo, C. A., Chen, F. E., Ewing, J. C., Garg, M. K., Godfrey, A. L., Knapper, S., McLornan, D. P., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15647 · Cited by 174
Self-citationBarosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H., Kiladijan, J., Lengfelder, E., Mesa, R., Mc Mullin, M. F., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08019.x · Cited by 173 · cited 1×
“This classification identifies a group of patients who have a poorer prognosis who may require or benefit from a change of treatment (Barosi et al , 2010) (Table 4) .”
BackgroundSelf-citationLeucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Gangat, N., Strand, J. J., Li, C., Wu, W., Pardanani, A. D., & Tefferi, A. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06674.x · Cited by 170 · cited 1×
“Cardiovascular risk factors (smoking, diabetes mellitus, arterial hypertension, hypercholesterolaemia) also contribute to thrombotic risk in PV (Barbui et al , 2017) (Landolfi et al , 2007) (Gangat et al , 2007).”
BackgroundBarbui, T., Carobbio, A., Rambaldi, A., & Finazzi, G. (2009) · Blood · doi:10.1182/blood-2009-02-206797 · Cited by 157 · cited 1×
“There is considerable published evidence of an association between increased WBC count and thrombosis risk in PV (Barbui et al , 2009; Caramazza et al , 2009) ((De Stefano et al , 2010; Barbui et al , 2015) (Cerquozzi et al , 2017).”
BackgroundCerquozzi, S., Barraco, D., Lasho, T. L., Finke, C. M., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., Gangat, N., & Tefferi, A. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0035-6 · Cited by 152 · cited 2×
“There is considerable published evidence of an association between increased WBC count and thrombosis risk in PV (Barbui et al , 2009; Caramazza et al , 2009) ((De Stefano et al , 2010; Barbui et al , 2015) (Cerquozzi et al , 2017).”
BackgroundJames, C., Ugo, V., Casadevall, N., Constantinescu, S. N., & Vainchenker, W. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.10.003 · Cited by 150 · cited 1×
“The JAK 2 V617F mutation can be found in over 95% of PV patients (James et al , 2005) and an exon 12 mutation in most remaining patients (Scott et al , 2007).”
BackgroundHarrison, C. N., Koschmieder, S., Foltz, L. M., Guglielmelli, P., Flindt, T., Koehler, M., Mathias, J., Komatsu, N., Boothroyd, R. N., Spierer, A., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3082-y · Cited by 149 · cited 1×
“Disease-related PV symptoms, such as microvascular disturbance, pruritus (which may be excruciat-ing), migraine-type headache and fatigue, may also be presenting features which can significantly impact on quality of life (Harrison et al , 2017).”
BackgroundSelf-citationGenetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases
Bento, C., Percy, M. J., Gardie, B., Maia, T. M., van Wijk, R., Perrotta, S., Ragione, F. D., Almeida, H., Rossi, C., Girodon, F., et al. (2013) · Human Mutation · doi:10.1002/humu.22448 · Cited by 147
Self-citationFinazzi, G., Vannucchi, A. M., Martinelli, V., Ruggeri, M., Nobile, F., Specchia, G., Pogliani, E. M., Olimpieri, O. M., Fioritoni, G., Musolino, C., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12332 · Cited by 128 · cited 1×
“Givinostat was assessed in a phase 2 study of PV unresponsive to HC monotherapy with response rates in the order of 50% and with high rates of improvement in pruritus (Finazzi et al , 2013).”
Bench, A. J., White, H., Foroni, L., Godfrey, A. L., Gerrard, G., Akiki, S. J., Awan, A., Carter, I. W. J., Goday‐Fernández, A., Langabeer, S. E., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12075 · Cited by 122 · cited 2×
“%) should be interpreted in the context of clinical, haematological and other laboratory findings (Bench et al , 2013).”
BackgroundMethodSelf-citationSamuelsson, J., Hasselbalch, H. C., Bruserud, Ø., Temerinac, S., Brandberg, Y., Merup, M., Linder, O., Björkholm, M., Pahl, H. L., Birgegård, G., et al. (2006) · Cancer · doi:10.1002/cncr.21900 · Cited by 116
Vannucchi, A. M., Verstovšek, S., Guglielmelli, P., Grießhammer, M., Burn, T. C., Naim, A. B., Paranagama, D. C., Marker, M., Gadbaw, B., & Kiladjian, J. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2994-x · Cited by 110 · cited 2×
“Data published from this study also suggested that molecular responses can occur, perhaps to the same extent as with IFN (Pieri et al , 2015; Vannucchi et al , 2017) and that even profoundly iron deficient patients can normalise their iron parameters with ruxolitinib therapy (Verstovsek et al ,…”
ResultRuxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1502524 · Cited by 108
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis
McMullin, M. F., Reilly, J. T., Campbell, P., Bareford, D., Green, A. R., Harrison, C. N., Conneally, E., on behalf of the National Cancer Research Institute, M. D. S., Ryan, K., & on behalf of the British Committee for Standards in Haematology (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06741.x · Cited by 106 · cited 1×
“The previous guideline was published in 2005 (McMullin et al , 2005) with an amendment in 2007 (McMullin et al , 2007) to update the diagnostic criteria following the discovery of the JAK 2 mutation in patients with polycythaemia vera (PV).”
MethodSelf-citationWhite blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study
Barbui, T., Masciulli, A., Marfisi, M. R., Tognoni, G., Finazzi, G., Rambaldi, A., & Vannucchi, A. M. (2015) · Blood · doi:10.1182/blood-2015-04-638593 · Cited by 105 · cited 2×
“Once treatment is initiated, cardiovascular events occur more frequently in patients with less stringent Hct control (Marchioli et al , 2013) and when the WBC count remains elevated > 11 9 10 9 /l (Barbui et al , 2015).”
Camps, C., Petousi, N., Bento, C., Cario, H., Copley, R. R., McMullin, M. F., van Wijk, R., Ratcliffe, P. J., Robbins, P. A., & Taylor, J. C. (2016) · Haematologica · doi:10.3324/haematol.2016.144063 · Cited by 101
Self-citationLarsen, T. S., Iversen, K. F., Hansen, E., Mathiasen, A. B., Marcher, C. W., Frederiksen, M., Larsen, H., Helleberg, I., Riley, C. H., Bjerrum, O. W., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.06.012 · Cited by 96 · cited 1×
“This agent is of particular interest due to its anti-clonal activity as demonstrated by molecular (as assessed by mutation burden of JAK 2 V617F) and histological remissions (Larsen et al , 2009) (Stauffer Larsen et al , 2013).”
BackgroundMesa, R. A., Vannucchi, A. M., Yacoub, A., Zachée, P., Garg, M. K., Lyons, R. M., Koschmieder, S., Rinaldi, C. R., Byrne, J., Hasan, Y., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14382 · Cited by 94
Self-citationInapparent Polycythemia Vera: An Unrecognized Diagnosis
Lamy, T., Devillers, A., Bernard, M., Moisan, A., Grulois, I., Drénou, B., Amiot, L., Fauchet, R., & Prisé, P. Y. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00351-8 · Cited by 86 · cited 1×
“It should also be noted that Hct is a poor surrogate of RCM in patients who have had splanchnic vein thrombosis (Lamy et al , 1997), and these high-risk patients are best managed with standard blood count targets regardless of blood count parameters at diagnosis.”
BackgroundLarsen, T. S., Møller, M. B., de Stricker, K., Nørgaard, P. H., Samuelsson, J., Marcher, C. W., Andersen, M. T., Bjerrum, O. W., & Hasselbalch, H. C. (2009) · Hematology · doi:10.1179/102453309x12473408860587 · Cited by 86 · cited 1×
“This agent is of particular interest due to its anti-clonal activity as demonstrated by molecular (as assessed by mutation burden of JAK 2 V617F) and histological remissions (Larsen et al , 2009) (Stauffer Larsen et al , 2013).”
BackgroundÁlvarez‐Larrán, A., Martinez-Aviles, L. M., Hernández‐Boluda, J. C., Ferrer‐Marín, F., Antelo, M. L., Burgaleta, C., Mata, M. I., Xicoy, B., Martínez‐Trillos, A., Gómez‐Casares, M. T., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2152-7 · Cited by 81
Delic, S., Rose, D., Kern, W., Nadarajah, N., Haferlach, C., Haferlach, T., & Meggendorfer, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14269 · Cited by 80 · cited 2×
“More recently, mutations in a number of other genes, most commonly TET 2 and DNMT 3A, have been reported in PV (Delic et al , 2016) These gene mutations are not, however, disease-specific and have also been reported in healthy individuals (Gen-ovese et al , 2014; Jaiswal et al , 2014), limiting…”
BackgroundThe effect of arterial hypertension on thrombosis in low‐risk polycythemia vera
Barbui, T., Vannucchi, A. M., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Ruggeri, M., Randi, M. L., Cazzola, M., Rambaldi, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24583 · Cited by 76 · cited 2×
“Data published from this study also suggested that molecular responses can occur, perhaps to the same extent as with IFN (Pieri et al , 2015; Vannucchi et al , 2017) and that even profoundly iron deficient patients can normalise their iron parameters with ruxolitinib therapy (Verstovsek et al ,…”
BackgroundResultAbdulkarim, K., Ridell, B., Johansson, P. L., Kutti, J., Safai‐Kutti, S., & Andréasson, B. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01548.x · Cited by 75
Geyer, H. L., Scherber, R. M., Kosiorek, H., Dueck, A. C., Kiladjian, J., Xiao, Z., Slot, S., Zweegman, S., Sackmann, F., Fuentes, A. E. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9337 · Cited by 73 · cited 1×
“There is evidence that patients with inade-quately controlled PV, as determined by hydroxycarbamide (HC) use, splenomegaly and venesection requirements, have a significantly higher symptom score measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) (Geyer et al , 2016).”
MethodSelf-citationAndersen, C. L., McMullin, M. F., Ejerblad, E., Zweegman, S., Harrison, C. N., Fernandes, S., Bareford, D., Knapper, S., Samuelsson, J., Löfvenberg, E., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12416 · Cited by 72 · cited 1×
“Two HDACi have been tested in PV in phase 2 trials: vorinostat in a trial of PV and ET achieved a response rate of 35% but with a very high drop-out rate because of adverse events (Andersen et al , 2013).”
MethodSelf-citationWhitehead, T. P., Robinson, D., Allaway, S. L., & HALE, A. C. (1995) · PubMed · Cited by 68
Álvarez‐Larrán, A., Ancochea, Á., Garcia, M., Climent, F., García‐Pallarols, F., Angona, A., Senín, A., Barranco, C., Martinez-Aviles, L. M., Serrano, S., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12990 · Cited by 67
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients
Álvarez‐Larrán, A., Bellosillo, B., Martinez-Aviles, L. M., Saumell, S., Salar, A., Abella, E., Gimeno, E., Serrano, S., Florensa, L., Sánchez, B., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07804.x · Cited by 63
Madelung, A. B., Bondo, H., Stamp, I. M., Loevgreen, P., Nielsen, S. L., Lauritzen, A. M. F., Knudsen, H., Ehinger, M., Dahl‐Sørensen, R. B., Mortensen, N. B., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23554 · Cited by 60 · cited 2×
“…several studies have reported high rates of non-consensus or failure to reach a histological diagnosis in patients with PV (Koopmans et al , 2011; Madelung et al , 2013) (Alvarez-Larr (cid:1) an et al , 2014a) Given the uncertain utility of bone marrow histology in the diagnosis of uncomplicated…”
BackgroundBarosi, G., Tefferi, A., Besses, C., Birgegård, G., Cervantes, F., Finazzi, G., Gisslinger, H., Grießhammer, M., Harrison, C. N., Hehlmann, R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.250 · Cited by 55 · cited 1×
“These are a valuable set of measures to assess treatment outcome with consistency across clinical trials but are not as useful in clinical practice (Barosi et al , 2015).”
BackgroundSelf-citationPieri, L., Pancrazzi, A., Pacilli, A., Rabuzzi, C., Rotunno, G., Fanelli, T., Guglielmelli, P., Fjerza, R., Paoli, C., Verstovšek, S., et al. (2015) · Blood · doi:10.1182/blood-2015-01-624536 · Cited by 48 · cited 6×
“Numerous single centre studies have observed that IFN-a can be successfully used to normalise blood counts, reduce splenomegaly and prevent thrombosis in PV (Silver, 2006) It is also effective in many patients in reducing pruritus (Taylor et al , 1996).”
ResultInfluentialVerstovšek, S., Harrison, C. N., Kiladjian, J., Miller, C. B., Naim, A. B., Paranagama, D. C., Habr, D., & Vannucchi, A. M. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.032 · Cited by 40 · cited 1×
“…published from this study also suggested that molecular responses can occur, perhaps to the same extent as with IFN (Pieri et al , 2015; Vannucchi et al , 2017) and that even profoundly iron deficient patients can normalise their iron parameters with ruxolitinib therapy (Verstovsek et al , 2017).”
ResultSelf-citationGowin, K. L., Jain, T., Kosiorek, H., Tibes, R., Camoriano, J. K., Palmer, J. M., & Mesa, R. A. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.006 · Cited by 40 · cited 2×
“…(Kiladjian et al , 2006) (Quint (cid:1) as-Cardama et al , 2009) Comparable results have been noted in single-centre studies (Cris (cid:4) a et al , 2017; Gowin et al , 2017) A Phase III study of PEG - a -2a versus HC as first-line treatment for high-risk PV is underway and interim analysis shows…”
ResultHansen, I. O., Sørensen, A. L., & Hasselbalch, H. C. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12787 · Cited by 38 · cited 1×
“A higher incidence of second malignancies has been seen in a small cohort of patients treated with HC compared to interferon (IFN) alone (Hansen et al , 2017), particularly non-melanoma skin cancers, and this has been seen in population-based studies with increased risk of non-melanotic skin cancer…”
ResultMascarenhas, J. O., Prchal, J. T., Rambaldi, A., Mesa, R. A., Berenzon, D. P., Yacoub, A., Harrison, C. N., McMullin, M. F., Vannucchi, A. M., Ewing, J. C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.479.479 · Cited by 31 · cited 1×
“…results have been noted in single-centre studies (Cris (cid:4) a et al , 2017; Gowin et al , 2017) A Phase III study of PEG - a -2a versus HC as first-line treatment for high-risk PV is underway and interim analysis shows no significant advantage for PEG - a -2a over HC (Mascarenhas et al , 2016).”
ResultSelf-citationThe relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study
Perricone, M., Polverelli, N., Martinelli, G., Catani, L., Ottaviani, E., Zuffa, E., Franchini, E., Dizdari, A., Forte, D., Sabattini, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16744 · Cited by 30 · cited 1×
“If the result is reproducible and does not represent a false positive, this finding may provide support for a diagnosis of a PV in a patient with otherwise unexplained, significant erythrocyto-sis (Perricone et al , 2017).”
ResultTreatment Target in Polycythemia Vera
McMullin, M. F., Harrison, C. N., & Kiladjian, J. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1301262 · Cited by 26
Self-citationBone marrow features of diagnostic impact in erythrocytosis
Thiele, J., Kvasnicka, H. M., & Diehl, V. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1030-8 · Cited by 23 · cited 1×
“Bone marrow histology may be helpful in distinguishing PV from secondary erythrocytosis (Thiele et al , 2005).”
BackgroundGómez, M., Guillem, V. M., Pereira, A., Ferrer‐Marín, F., Álvarez‐Larrán, A., Kerguelen, A., Estrada, N., Martínez‐López, J., Angona, A., Amat, P., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12588 · Cited by 21
Ahn, I. E., Natelson, E. A., & Rice, L. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.05.015 · Cited by 13 · cited 1×
“Retrospective reports of anagrelide used in combination with HC in PV have shown that it is effective at lowering the platelet count and it may be useful in combination when an elevated platelet count is an issue (Ahn et al , 2013).”
Background
Metadata
- Authors
- McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C., Chen, F., Ewing, J., Garg, M., Godfrey, A., S, S. K., McLornan, D. P., Nangalia, J., Sekhar, M., Wadelin, F., Mead, A. J., & the BSH Committee
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2018-11-27
- Volume
- 184
- Issue
- 2
- Pages
- 176-191
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2903319422
- Cited by
- 161
- References
- 70
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.